Journal Menu
► ▼ Journal Menu-
- Pharmaceutics Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserNeed Help?
Announcements
14 November 2025
World Diabetes Day, 14 November 2025
World Diabetes Day will take place on 14 November 2025, under the theme “Diabetes and well-being”. Diabetes is a major cause of blindness, kidney failure, heart attack, stroke and lower limb amputation. A healthy diet, physical activity and avoiding tobacco use can prevent or delay type 2 diabetes. In addition, diabetes can be treated and its consequences avoided or delayed with medication, regular screening and treatment for complications.
In recognition of this important day, we recommend the following related articles, Special Issues and journals spanning multidisciplinary fields, including clinical medicine, biology and material sciences. We believe th.at promoting such research contributes to enhanced public awareness of innovative ideas regarding the prevention, treatment and care of diabetes. This World Diabetes Day, 14 November, let us put well-being at the heart of diabetes care and start the change for a better life with diabetes.

|
Biology & Life Science |
Medicine & Pharmacology |
||
|
|
|||
|
Chemistry & Material Science |
|||
|
|
|
||
|
|
|

“New-Onset Diabetes After Transplantation in Renal Recipients: A Pilot Comparative Study of Immediate vs. Extended-Release Tacrolimus Formulation”
by Ioana Adela Ratiu, Florin Bănică, Corina Moisa, Bianca Pașca, Daniela Gîtea, Iulia Dana Grosu, Gabriel Cristian Bako, Oliviu Voștinaru, Wael Abu Dayyih and Lorena Filip
Pharmaceuticals 2025, 18(10), 1532; https://doi.org/10.3390/ph18101532
“From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments”
by Francesc Cabré, Josep J. Centelles and Marta Cascante
Pharmaceutics 2025, 17(9), 1125; https://doi.org/10.3390/pharmaceutics17091125
“Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy”
by Laila Schneidewind, Bernhard Kiss, Friedemann Zengerling, Annemarie Uhlig, Niklas Klümper, Thomas Büttner, Julia Heinzelbecker, Thomas Elegeert, Cem Aksoy, Cindy Rönnau et al.
Biologics 2025, 5(3), 20; https://doi.org/10.3390/biologics5030020
“Gene–Diet Interactions in Diabetes Mellitus: Current Insights and the Potential of Personalized Nutrition”
by Angeliki Kapellou, Effie Salata, Dimitrios Miltiadis Vrachnos, Sevastiani Papailia and Spiros Vittas
Genes 2025, 16(5), 578; https://doi.org/10.3390/genes16050578
“Anti-Diabetic Therapies and Cancer: From Bench to Bedside”
by Dimitris Kounatidis, Natalia G. Vallianou, Irene Karampela, Eleni Rebelos, Marina Kouveletsou, Vasileios Dalopoulos, Petros Koufopoulos, Evanthia Diakoumopoulou, Nikolaos Tentolouris and Maria Dalamaga
Biomolecules 2024, 14(11), 1479; https://doi.org/10.3390/biom14111479
“Untargeted and Targeted Lipidomics Unveil Dynamic Lipid Metabolism Alterations in Type 2 Diabetes”
by Li Feng, Bingshu He, Jianzhen Xia and Zhonghua Wang
Metabolites 2024, 14(11), 610; https://doi.org/10.3390/metabo14110610
“Quality of Dietetic Patient Education Materials for Diabetes and Gastrointestinal Disorders: Where Can We Do Better?”
by Kelly Lambert, Olivia Hodgson and Claudia Goodman
Dietetics 2024, 3(3), 346-356; https://doi.org/10.3390/dietetics3030026
“Biomaterials Designed to Modulate Reactive Oxygen Species for Enhanced Bone Regeneration in Diabetic Conditions”
by Mingshan Li, Zhihe Zhao and Jianru Yi
J. Funct. Biomater. 2024, 15(8), 220; https://doi.org/10.3390/jfb15080220
“The Interrelationship between Diabetes Mellitus and Emotional Well-Being: Current Concepts and Future Prospects”
by Polyxeni Mangoulia, Charalampos Milionis, Eugenia Vlachou and Ioannis Ilias
Healthcare 2024, 12(14), 1457; https://doi.org/10.3390/healthcare12141457
“Are Hyperglycemia-Induced Changes in the Retina Associated with Diabetes-Correlated Changes in the Brain? A Review from Zebrafish and Rodent Type 2 Diabetes Models”
by Kaylee Augustine-Wofford, Victoria P. Connaughton and Elizabeth McCarthy
Biology 2024, 13(7), 477; https://doi.org/10.3390/biology13070477
“Interleukin-6 as a Director of Immunological Events and Tissue Regenerative Capacity in Hemodialyzed Diabetes Patients”
by Maria-Florina Trandafir, Octavian Savu, Daniela Pasarica, Coralia Bleotu and Mihaela Gheorghiu
Med. Sci. 2024, 12(2), 31; https://doi.org/10.3390/medsci12020031
“Euonymus alatus Extract Reduces Insulin Resistance in db/db Mice by Regulating the PI3K–AKT Pathway”
by Seoung-Uk. Lee, Pallavi Gurung, Til Bahadur Thapa Magar, Junmo Lim, Rajeev Shrestha, Yoon-Hee Kim and Yong-Wan Kim
Int. J. Transl. Med. 2024, 4(2), 286-297; https://doi.org/10.3390/ijtm4020018
“Personalized Diabetes Management with Digital Twins: A Patient-Centric Knowledge Graph Approach”
by Fatemeh Sarani Rad, Rasha Hendawi, Xinyi Yang and Juan Li
J. Pers. Med. 2024, 14(4), 359; https://doi.org/10.3390/jpm14040359
“NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay”
by Simona Cernea
Life 2024, 14(2), 272; https://doi.org/10.3390/life14020272
“Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight”
by Franklyn Nonso Iheagwam, Amarachi Joy Joseph, Eniola Deborah Adedoyin, Olawumi Toyin Iheagwam and Samuel Akpoyowvare Ejoh
Pathophysiology 2025, 32(1), 9; https://doi.org/10.3390/pathophysiology32010009
“Is Tirzepatide the New Game Changer in Type 2 Diabetes?”
by Giuseppe Lisco, Olga Eugenia Disoteo, Vincenzo De Geronimo, Anna De Tullio, Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Emilio Jirillo and Vincenzo Triggiani
Endocrines 2024, 5(1), 72-86; https://doi.org/10.3390/endocrines5010005
“Fostering Resilience and Wellness: The Synergy of Mindful Eating and the Mediterranean Lifestyle”
by Efstratios Christodoulou, Georgia-Eirini Deligiannidou, Christos Kontogiorgis, Constantinos Giaginis and Antonios E. Koutelidakis
Appl. Biosci. 2024, 3(1), 59-70; https://doi.org/10.3390/applbiosci3010004
“The Main Risk Factors in Type 2 Diabetes for Cognitive Dysfunction, Depression, and Psychosocial Problems: A Systematic Review”
by Maarja Randväli, Toomas Toomsoo and Jekaterina Šteinmiller
Diabetology 2024, 5(1), 40-59; https://doi.org/10.3390/diabetology5010004
“Chronic Kidney Disease in the Older Adult Patient with Diabetes”
by Raja Ravender, Maria-Eleni Roumelioti, Darren W. Schmidt, Mark L. Unruh and Christos Argyropoulos
J. Clin. Med. 2024, 13(2), 348; https://doi.org/10.3390/jcm13020348

|
“Clinical Genetics of Diabetes” |
“Healthy Habits of Diabetes: Prevention, Intervention and Management Strategies” |
|
|
|
|
“Emerging Therapies for Diabetes and Obesity” |
“From Monitoring to Management: Addressing Challenges in Type 1 and Type 2 Diabetes Care” |
|
|
|
|
“Experimental Biology: From Methods to Applications—Under the Auspices of the Italian Society of Experimental Biology, SIBS-1925” |
“Clinical Translation of Technological Innovations in Diabetes Therapeutics” |
|
|
|
|
“Immune Responses in Type 1 Diabetes” |
“Diabetes and Cardiovascular Diseases in the New Era” |
|
|
|
|
“Interdisciplinary Approach to Diabetes Mellitus: From Pathophysiology to Diagnosis and Therapeutic Challenges: 2nd Edition” |
“Metabolic Signature of Type 2 Diabetes, Insulin Resistance, and Obesity Triad” |
|
|
|
|
“Diabetes and Its Complications: From Research to Clinical Practice” |
“Tailored Lifestyle and Behaviour Change Interventions for Prevention of Diabetes” |
|
|
|
|
“Clinical Nutrition in the Era of Precision: Bioactives, Microbiome and Targeted Dietetic Interventions” |
“Feature Papers in International Journal of Translational Medicine” |
|
|
|
5 November 2025
Meet Us at the 18th China Pharmaceutical Preparation Conference, 21–23 November 2025, Nanjing, China
Conference: The 18th China Pharmaceutical Preparation Conference
Date: 21–23 November 2025
Location: Nanjing, China
Booth number: A33
MDPI will be attending the 18th China Pharmaceutical Preparation Conference as an exhibitor, welcoming researchers from diverse backgrounds to visit and share their latest ideas.
This conference, themed “Research and Translation of Advanced Pharmaceutical Formulations”, invites renowned experts from domestic universities, research institutes, pharmaceutical companies, R&D units, medical institutions, and management agencies to deliver keynote speeches and special presentations. The conference will focus on research in the field of advanced pharmaceutical formulations, discussing topics such as advanced formulations, modern formulations, novel sustained-release and controlled-release formulations, topical formulations, pharmaceutical excipients, and packaging systems. It aims to establish a high-level academic exchange platform for pharmaceutical formulations, promote the upgrading of the pharmaceutical formulation industry, jointly contribute to the innovative development of the pharmaceutical industry, and support the country's efforts to become a pharmaceutical powerhouse.
The following MDPI journals will be represented:
- Pharmaceutics;
- Sci. Pharm.;
- Psychoactives;
- Future Pharmacology;
- JNT;
- JPBI;
- Pharmacoepidemiology;
- DDC.
If you are planning to attend this conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information, please visit https://cpc2025.sciconf.cn/.
4 November 2025
MDPI INSIGHTS: The CEO's Letter #28 - WSF11, Nobel Laureates, Proofig AI, Romania Summit, STM and FBF
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts

Highlights from the 11th World Sustainability Forum in Barcelona
I’m pleased to share some highlights from the 11th World Sustainability Forum (WSF 11), held in Barcelona on 2–3 October 2025 under the theme Sustainable and Resilient Cities.
Why WSF matters
The WSF series is a flagship initiative for MDPI and is supported by the MDPI Sustainability Foundation. It serves as a transdisciplinary platform for researchers, policymakers, and stakeholders to engage on sustainability challenges. WSF is now held annually as part of our commitment to maintain momentum in the sustainability discourse.
|
|
|
|
This year’s Barcelona edition focused on urban resilience, landscape design, and social community impact in the sustainability space. Over 48 hours of sessions, we brought together leading minds across disciplines to translate vision into practice. With participants from 53 countries across all continents, WSF 11 was truly global in scope.

“WSF is now held annually as part of our commitment to maintain momentum in the sustainability discourse”
What made WSF 11 especially successful (from my vantage point) was the level of positive engagement with our participants. Chief editors, researchers, and attendees repeatedly told me how professionally executed the event was, highlighting the high energy, logistical smoothness and quality of MDPI’s event management. That kind of recognition from peers really builds our reputation as more than just a publisher, but as a convener of meaningful scientific dialogue.
Our conferences are a form of experiential marketing as they create memorable and immersive connections between a brand and attendees. These positive associations build promotion and brand loyalty, ultimately impacting the MDPI’s trust and reputation for the better.
WSF 11: By the numbers
Here’s a quick snapshot of WSF 11’s scale and reach:
- 181 registrations across global participants.
- 8 keynote speakers and 5 invited speakers.
- 144 abstracts accepted (over 355 submitted), resulting in 75 short talks and 69 posters.
- 53 countries were represented across all continents, making it a truly international event.
- First time that we ran parallel sessions for WSF (an ambitious program).
- A dedicated awards ceremony to honour outstanding sustainability research: World Sustainability Award (WSA) x 2 winners, and Emerging Sustainability Leader Award (ESLA) x 3 winners.
Interviews with our World Sustainability Award Winners
One of the most rewarding parts of WSF is recognizing researchers whose work advances sustainability in powerful ways. In our Blog series, Daniella Maritan-Thomson (Content Specialist, MDPI) interviewed the two winners of the World Sustainability Award, Professor Dr. Stuart Pimm and Dr. Abdelbagi M. Ismail, who offered insights to the human side of sustainability research, the people behind the data, and the stories behind the science.
|
|
Prof. Stuart Pimm, whose decades of conservation work make him a leader in biodiversity preservation, reflected on his WSF Award experience and research in this interview: [Interview: Prof Stuart Pimm] |
|
|
Dr. Abdelbagi M. Ismail, an expert in crop improvement and winner of the WSF Award, shares his journey and perspectives here: [Interview: Dr Abdelbagi M. Ismail] |
“Our conferences create memorable and immersive connections”
Emerging Sustainability Leader Award winners

Stefan Tochev (CEO, MDPI), Prof. Dr. Vhahangwele Masindi, Dr. Katya Rhodes, and Prof. Dr. Myriam Ertz (left to right).
We also recognized three recipients of the Emerging Sustainability Leader Award: Prof. Dr. Vhahangwele Masindi, Dr. Katya Rhodes, and Prof. Dr. Myriam Ertz, for their contributions as early-career researchers advancing sustainability through innovation, impact, and academic excellence across the field.
What this means for MDPI
- Building our global identity in events
WSF is a marquee MDPI event, not just a gathering, but a statement of how we wish to position ourselves in the global sustainability ecosystem. The positive feedback helps us build on our approach for future editions, so that we remain a reference point for quality, relevance, and engagement. - Expanding capacity across offices
The success of WSF 11 in Barcelona’s would not have happened without great teamwork from Basel, Barcelona, Romania, the UK, and the APAC Conference team. Thanks to everyone for their work to bring this ambitious event to life. - Supporting MDPI’s mission
At this event, I had the opportunity to present on MDPI's role in Open Access, sustainability publishing, and the intersection of science and policy. WSF is not only about the science; it’s also a platform for us to position MDPI as a thought leader and a collaborator in shaping the future of sustainable research.
I look forward to the WSF momentum as we work towards WSF 12 in Hong Kong, which is scheduled for August 2026.

MDPI Colleagues at the 11th World Sustainability Forum in Barcelona, Spain, 2–3 October 2025.
Impactful Research

Celebrating 2025 Nobel Laureates who have published with MDPI
October is always an inspiring month in science. It’s when the world turns its attention to the Nobel Prize announcements, recognizing discoveries that have changed how we understand the world.
Over the years, many distinguished researchers who have received the Nobel Prize have chosen to publish their work with MDPI. These are scientists whose breakthroughs have shaped entire fields of research, and who have entrusted our Open Access journals to share their findings with the world.
“The work we support can be world-class and world-changing”
Congratulations to the 2025 Laureates
Dozens of Nobel Laureates have published in our journals: as at 2024, more than 40 laureates had contributed over 115 articles across more than 35 MDPI journals. Congratulations to the three 2025 Nobel prize-winners who have published with MDPI during their careers. Below are links to their MDPI publications and announcements for further reading:
- Omar M. Yaghi (Chemistry)
- Awarded for his pioneering work on metal-organic frameworks (MOFs). MDPI published his article “Covalent Organic Frameworks: Organic Chemistry Beyond the Molecule” in Molecules (2017).
- MDPI Announcement: https://www.mdpi.com/news/13455
- Nobel Prize in Chemistry – The Science Behind the Prize
- Shimon Sakaguchi (Medicine)
- Recognized for discoveries in immune-system self-tolerance and regulatory T-cells. Published in Cancers (2021).
- MDPI Announcement: https://www.mdpi.com/news/13443
- Nobel Prize in Physiology or Medicine – The Science Behind the Prize
- John M. Martinis (Physics)
- Recognized for quantum tunnelling in electrical circuits. MDPI’s Journal of Nuclear Engineering (2025) includes his co-authored work.
- MDPI Announcement: https://www.mdpi.com/news/13450
- Nobel Prize in Physics – The Science Behind the Prize
These connections strengthen our mission to make research freely available and ensure that transformative ideas reach the widest possible audience.
Publishing at the leading edge of knowledge
The privilege of hosting such contributors resonates deeply with our editorial teams. It shows that top-tier scientific work has a home at MDPI, which builds our visibility in the research community. It signals that our publishing model, our editorial workflows, and our commitment to Open Access are respected at the very highest levels of science. It also gives our authors, reviewers, editors and staff the message that the work we support can be world-class and world-changing.
Publishing at the leading edge of knowledge isn’t just about individual papers – it’s about the ecosystem of support, transparency, and accessibility that makes discovery possible. Let’s continue to build a publishing platform and provide a service that attracts and enables both everyday research and the breakthroughs of tomorrow.
Inside MDPI

Strengthening Research Integrity: MDPI partners with Proofig AI
I’m pleased to share that MDPI has entered a multi-year partnership with Proofig AI, a leader in AI-driven proofing and integrity software for scientific publishing. This follows the success of our pilot program, in which Proofig AI proved highly effective in detecting duplicated, altered, and manipulated images across biomedical submissions.
Safeguarding the credibility of the research we publish
Research integrity is at the core of MDPI’s mission. The life sciences, in particular, face increasing risks of image-related issues due to advanced editing tools and generative AI. By integrating Proofig AI into our workflows, we improve our ability to detect issues early, reduce post-publication corrections, and safeguard the credibility of the research we publish.
Pilot outcomes
- Successful detection of duplicated confocal and histology images, even when altered to disguise similarities.
- Early results showed a significant drop in post-publication image manipulation flags year-on-year.
- Positive feedback from editors and staff highlighted the tool’s ease of use and reliability.

Dr. Dror Kolodkin-Gal (co-founder and CEO of Proofig AI) said:
“The MDPI team conducted a highly professional and carefully monitored pilot, achieving excellent results in detecting problematic images.
Their fast and effective integration process was impressive, and we are excited to contribute to this important collaboration.”

Sanita Meijere (IT Product and Project Manager, MDPI), shared:
“For more than a year, we’ve tested all the available image manipulation detection tools. Proofig AI’s quality and ease of use, alongside positive feedback from our internal users, made their software a clear stand-out.
We’re thrilled to be moving forward with this partnership, ensuring we do our utmost to protect MDPI’s biomedical journals. Using this advanced image proofing software reaffirms MDPI’s commitment to maintaining the highest standards in research integrity.”
Raising the bar for integrity
This partnership sets a new benchmark for quality control in biomedical publishing.

As Tim Tait-Jamieson (Head of Publication Ethics, MDPI), explains:
“The life sciences are disproportionately affected by research integrity issues, making vigilance in this field especially critical. This is driven, in part, by the increasing sophistication of image editing software and generative AI.
Whether accidental or deliberate, image manipulation can have a lasting impact on credibility. By integrating Proofig AI into our editorial workflows, we strengthen our ability to detect scientific misconduct early and reduce post-publication amendments.”
Faster and more accurate quality control
Proofig will automatically flag potentially problematic images during submission checks, giving our editors more confidence in the integrity of manuscripts and freeing up time to focus on editorial decisions. The tool will also reduce the burden of manual checks, while supporting faster and more accurate quality control. This partnership reinforces MDPI's reputation as a publisher that takes integrity seriously and continues to invest in tools to support authors, editors, and reviewers alike.
A big thank-you to all colleagues who supported the pilot and rollout. You can read more in our MDPI Blog post.
Coming Together for Science

The MDPI Romania Summit 2025
On 21–22 October, I had the pleasure of joining our colleagues in Bucharest for the MDPI Romania Summit 2025. The event was organized by our Romania Marketing team, with support from colleagues across our Romanian offices. It brought together academics, policymakers, and collaborators to discuss the country’s evolving research landscape.
Over two days, we welcomed more than 30 participants, including Editorial Board Members, Guest Editors, and policy-makers from the Romanian research and education sectors, including representatives from the Romanian Academy and the National Commission for the Accreditation of Academic Titles (CNATDCU).
The discussions and presentations reflected the strength and growth of Romania’s research community and its active engagement in Open Access publishing.
|
|
|
|
“The discussions and presentations reflected the strength and growth of Romania’s research community”
Romania’s role in Open Access
Romania loves Open Access and has emerged as one of MDPI’s most engaged national research communities. The numbers speak for themselves:
- 67% of all publications in Romania were Open Access in 2024.
- MDPI accounts for 39% of the country’s total OA publications (14,779 in 2024).
- Over the last five years (2020–2024), Romanian institutions published over 33,000 papers with MDPI.
- There are 460 active Editorial Board Members from Romania, including 8 Chief Editors.
- 29 institutions are part of our Institutional Open Access Program (IOAP), with 8 new members joining in 2025.
These numbers reflect the trust and reliable partnership we have built with the Romanian academic community.
Highlights from the Summit
The program covered a wide range of topics from MDPI’s achievements and updates to our editorial processes, peer-review quality, AI in publishing, IOAP and Open Access funding models, and publication ethics.
|
|
|
|
|
|
|
|
Agenda Highlights:
- MDPI Introduction, Performance & Achievements, and Collaboration with Romania – Stefan Tochev (CEO, MDPI).
- Trust the Process: Editorial Workflow and Quality in Publishing – Dr. Liliane Auwerter (Scientific Review Group).
- Publication Ethics at MDPI: Safeguarding the Integrity of the Published Scholarly Record – Diana Cristina Apodaritei (Research Integrity Specialist).
- Institutional Partnerships – Becky Castellon (Institutional Partnerships Manager, MDPI).
- AI in Publishing and MDPI's Actions – Sanita Meijere (AI Product Manager).
- Closing Remarks – Stefan Tochev (CEO, MDPI).
Participants shared feedback and ideas for future collaborations, including organizing author workshops, possible conference collaborations, and strengthening our engagement with national institutions such as the Ministry of Education and Research and the National Council of Romanian Rectors.
As Acad. Dr. Nicolae-Victor Zamfir, Vice President of the Romanian Academy, noted during the discussions:
“The organization of the event is very timely, because MDPI is a publishing house in full development and expansion. The opinion of researchers is important for increasing the quality of published works.”
A collaborative future
Events like this remind us how essential it is to engage locally and listen directly to the voices of our editors, authors, and institutional partners. They help us build relationships, improve our understanding of the local market, and align our shared goals in advancing Open Access and research quality.
Thank you to everyone involved, especially our Romania Marketing team, who organized the event, and to all colleagues who continue to build relationships with our academic communities around the world.

Thank you!
A special thank-you to the Romanian Marketing team and all colleagues behind the scenes who made this Summit such a success. Your efforts are greatly appreciated. We look forward to building on this momentum with future Summits in Europe and beyond.
Closing Thoughts

STM and FBF 2025: Connecting Through Science and Publishing

Stefan Tochev (CEO, MDPI), Constanze Schelhorn (Head of Indexing, MDPI) at STM Conference, Frankfurt, 14 October 2025.
On 13–14 October, I attended the STM Frankfurt Conference 2025, my fourth visit to the Frankfurt event, and it continues to be one of the most valuable gatherings in our industry.
The STM meeting brings together the publishing community and key opinion leaders to speak on current trends and challenges shaping our industry.
This year’s theme – “Science Diplomacy: What is it and How Does it Work?” – unpacked the growing intersection of science, policy, and publishing.
Discussion topics ranged from what is science diplomacy and how publishers can contribute to global collaboration to how science communication can help maintain trust during an era of disruption.
I was joined by Dr. Constanze Schelhorn, our Head of Indexing, who met with representatives from Scopus, Web of Science, Digital Science, ProQuest, and other partners. These meetings give us a chance to share feedback on our collaborations, learn about new updates being developed, and build our relationships with indexing bodies.
“The STM meeting brings together the publishing community and key opinion leaders”
STM also provides a space to connect with industry peers, as I did with colleagues from Elsevier, Frontiers, Clarivate, Sage, and STM itself, reinforcing MDPI’s engagement within the broader publishing community. It was also nice to bump into some former colleagues and see them continuing to grow in their publishing careers.
At the Frankfurt Book Fair

The MDPI booth at the 2025 Frankfurt Book Fair.
Following STM, I spent the next day at the Frankfurt Book Fair (15–19 October) – one of the largest and most influential events in the publishing world.
It’s always inspiring to see the scale and energy of this global gathering, which spans everything from books and education to digital innovation and academic publishing.
We set up an MDPI booth to host discussions with partners, vendors, and researchers.
The Fair ran into the weekend, with colleagues from several MDPI departments attending to represent the company and connect with the scholarly community.
Events like STM and FBF are a nice reminder of how dynamic and interconnected our industry is, and how important it is for MDPI to continue taking part in global conversations about science, communication, and the future of publishing.
Chief Executive Officer
MDPI AG
16 October 2025
Pharmaceutics | Selected Editor’s Choice Articles Published in February 2025
Editor’s choice articles are selected based on suggestions from the Academic Editors of Pharmaceutics (ISSN: 1999-4923). The Editors select a small number of published articles that they consider to be particularly interesting to our readers or important in their respective fields of research. You are therefore invited to read the editor’s choice articles, a curated list of high-quality articles published in Pharmaceutics in February. The full list of editor’s choice articles can be viewed via the following link: https://www.mdpi.com/journal/pharmaceutics/editors_choice.
1. “A Step Towards Real-Time Release Testing of Pharmaceutical Tablets: Utilization of CIELAB Color Space”
by René Brands, Trieu Nam Le, Jens Bartsch and Markus Thommes
Pharmaceutics 2025, 17(3), 311; https://doi.org/10.3390/pharmaceutics17030311
Editor’s highlight: Authors developed a promising UV/Vis spectroscopy tool for real-time release in tableting, based entirely on mechanical models and capturing both the chemical composition and physical properties of the tablets such as porosity and tensile strength. This development can help to optimize the ejection position of a rotary tablet press. Interestingly, this system uses the in-line monitoring of physical tablet properties. Specifically, tablet porosity and tablet hardness are investigated in terms of tensile strength. Also, the system described by Brands and co-authors characterizes the tablet’s surface roughness by using a laser profilometer.
2. “C24 Ceramide Lipid Nanoparticles for Skin Wound Healing”
by Ji-Hye Lee, Jin-Hyun Kim, Tong-Il Hyeon, Khee-Tae Min, Se-Young Lee, Han-Chul Ko, Hong-Seok Choi, Kuk-Youn Ju, Young-Seok Cho and Tae-Jong Yoon
Pharmaceutics 2025, 17(2), 242; https://doi.org/10.3390/pharmaceutics17020242
Editor’s highlight: C24 ceramide was successfully encapsulated into lipid nanoparticles (C24-LNPs), significantly enhancing its water solubility and bioavailability, thereby offering a new strategy for skin wound healing. It is demonstrated through systematic in vitro and in vivo experiments that a C24-LNP effectively promotes keratinocyte proliferation and migration, activates the AKT/ERK signaling pathways, and accelerates epithelial regeneration and collagen synthesis, outperforming traditional EGF protein therapy. The research not only addresses the formulation challenges associated with the clinical application of ceramides but also sets the foundation for developing cost-effective and efficient skin regeneration therapies.
3. “Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers”
by Jazmín Torres, Johanna Karina Valenzuela Oses, Antonio María Rabasco-Álvarez, María Luisa González-Rodríguez and Mónica Cristina García
Pharmaceutics 2025, 17(2), 245; https://doi.org/10.3390/pharmaceutics17020245
Editor’s highlight: This review provides a systematic summary of the latest advances in endogenous stimuli-responsive liposomes for cancer treatment. The article is well-structured, offering detailed explorations of various smart liposomes, including pH-, enzyme-, redox-, reactive oxygen species (ROS)-, and hypoxia-responsive systems, and further elaborates on the design strategies and application advantages of dual- and multi-stimuli-responsive systems that integrate multiple triggers. A notable strength of this review lies in its focus not only on the design principles and response mechanisms of liposomes but also on their specific anti-cancer applications. It presents numerous cutting-edge research examples such as the co-delivery of multiple drugs and combination immunotherapy, demonstrating the significant potential of these nanocarriers in enhancing targeting efficiency, reducing side effects, and overcoming drug resistance. In addition, the article looks forward to emerging directions such as trackable liposomes with integrated diagnostic and therapeutic functions, reflecting the field's trend toward precision medicine. Overall, this review is comprehensive and insightful, successfully integrating fundamental design, mechanisms of action, and practical applications. It offers valuable perspectives on endogenous stimuli-responsive liposomes and serves as an important reference for researchers involved in cancer nanomedicine development.
4. “Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems”
by Ernesto J. Delgado-Pujol, Guillermo Martínez, David Casado-Jurado, Juan Vázquez, Jesús León-Barberena, David Rodríguez-Lucena, Yadir Torres, Ana Alcudia and Belén Begines
Pharmaceutics 2025, 17(2), 215; https://doi.org/10.3390/pharmaceutics17020215
Editor’s highlight: This is a comprehensive review of the usefulness of hydrogels and nanogels in developing smart drug delivery systems, updated to include the latest research.
These emerging materials are used for controlled and targeted drug release, making treatments smarter, more precise, and tailored to each patient. This interesting and thorough review explores their evolution, production methods, release mechanisms, and pharmaceutical applications, demonstrating their potential to transform personalised medicine. Although challenges in manufacturing and regulation remain, the future looks promising for smarter, more precise, and patient-centred therapies.
5. ”AI-Driven Innovation in Skin Kinetics for Transdermal Drug Delivery: Overcoming Barriers and Enhancing Precision”
by Nubul Albayati, Sesha Rajeswari Talluri, Nirali Dholaria and Bozena Michniak-Kohn
Pharmaceutics 2025, 17(2), 188; https://doi.org/10.3390/pharmaceutics17020188
Editor’s highlight: This review explores how is AI changing transdermal drug delivery. Recent breakthroughs have deepened our understanding of how the skin acts as a barrier—and how to overcome it for more effective therapies. But developing truly personalized TDDS means considering factors like skin type, body area, age, and hydration. The review explores how advanced models—like neural networks and machine learning algorithms—are making it easier to predict skin permeability and select the best TDDS for each situation.
6. “Emerging Trends in Snake Venom-Loaded Nanobiosystems for Advanced Medical Applications: A Comprehensive Overview”
by Álisson E. F. Alves, Anne B. C. Barros, Lindomara C. F. Silva, Lucas M. M. Carvalho, Graziela M. A. Pereira, Ana F. C. Uchôa, José M. Barbosa-Filho, Marcelo S. Silva, Karla P. O. Luna, Karla S. R. Soares et al.
Pharmaceutics 2025, 17(2), 204; https://doi.org/10.3390/pharmaceutics17020204
Editor’s highlight: In the 16th century, Paracelsus said, “All substances are poisons; there is none that is not a poison. It is the dose that differentiates a poison from a remedy.” This interesting and original review explores how dangerous poisons can be transformed into potential therapies for treating certain diseases using nanotechnology. The main composition of snake venom, its utility, and the associated challenges are discussed in the text. It also discusses the most commonly used nanosystems for immobilising snake venom and how nanoparticles can reduce toxicity and improve treatment precision. The review demonstrates the great potential of nanosystems in developing safer and more effective therapies based on these substances.
7. “Development of an Innovative Dual Construct for Targeted Drug Delivery in the Oral Cavity”
by Elena Mazzinelli, Ilaria Favuzzi, Marianna Messina, Giorgia Fratocchi, Federica Vincenzoni, Eleonora Santo Stefano, Francesco Cecconi, Carlo Lajolo, Alessia Basco, Raffaella Castagnola et al.
Pharmaceutics 2025, 17(2), 272; https://doi.org/10.3390/pharmaceutics17020272
Editor’s highlight: The research article, entitled 'Development of an Innovative Dual Construct for Targeted Drug Delivery in the Oral Cavity', investigates new approaches to treating oral lichen planus based on innovative buccal drug delivery systems. Current oral treatments are often limited in effectiveness by natural barriers such as mucus layers and constant saliva flow, which is especially challenging for chronic conditions such as oral lichen planus, where patient compliance and drug permanence in the oral cavity are critical. In this study, the authors present an innovative dual drug delivery system designed to address these challenges and control drug delivery, thereby improving residence time. They propose using PLGA nanoparticles loaded with dexamethasone to enable controlled drug release and effective cellular uptake, and chitosan-coated PLA fibres to provide strong mucoadhesion and ensure that the formulation stays in place, even under simulated saliva flow.
15 October 2025
MDPI’s Newly Launched Journals in September 2025
Nine new journals covering a range of subjects launched their inaugural issues in September 2025. We are excited to be able to share with you the newest research rooted in the value of open access.
We extend our sincere thanks to all Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.
Please feel free to browse and discover more about the new journals below.
|
Journal |
Founding Editor-in-Chief |
Journal Topics (Selected) |
|
|
Prof. Dr. Joseph G. Grzywacz, San José State University, USA |
family formation and dynamics; family relationships; family diversity and structure; family processes; family challenges; global perspectives of family | |
|
|
Prof. Dr. Chengkuo Lee, National University of Singapore, Singapore |
AIoT sensing technologies; distributed AI and federated learning; AI-enhanced edge analytics; sensor fusion in edge computing; low-power AI sensing; security and privacy in edge-AI systems; AI-driven optimization of IoT networks | |
|
|
Prof. Dr. Steven Paul Nistico, Sapienza University of Rome, Italy |
aesthetics; reconstructive surgery and plastic surgery; dermatology; oral and maxillofacial surgery; surgical procedures; non-surgical procedures | |
|
|
Prof. Dr. Mauro Tonelli, University of Pisa, Italy |
plasma physics and technology; atomic and molecular physics; nuclear physics; quantum physics and technology; dielectrics, ferroelectrics, and multiferroics; semiconductor physics and devices; engineering physics; material physics; biophysics| |
|
|
Prof. Dr. Sergej M. Ostojic, University of Agder, Norway; |
biochemical research methods; biochemistry and molecular biology; cell biology; clinical and medicinal chemistry; clinical neurology; endocrinology and metabolism; medicine, general and internal; nutrition and dietetics; toxicology | |
|
|
Prof. Dr. Michele Nappi, University of Salerno, Italy |
foundations and advancements in multimedia technologies; computational social media analytics; human–AI interaction in social contexts; multimedia understanding and generation for social insight; ethics, fairness, and privacy in multimedia systems | |
|
|
Prof. Dr. Philippe Gorce, Toulon University, France |
ergonomic design and evaluation of workspaces, tools, and equipment; biomechanical analysis and ergonomic interventions for musculoskeletal health; cognitive workload assessment and management; human-computer interaction (HCI) and user experience (UX) research; ergonomic wearables; AI-driven ergonomic assessment tools; neuroergonomics | |
|
|
Prof. Dr. Ronald Charles Sims, Utah State University, USA |
bioresources; bioproducts; bioenergy and biofuels; environmental protection; public health protection; biological waste treatment; biomass transformation; circular bioeconomy; bio-based materials and chemicals; bioresidues | |
|
|
Prof. Dr. M. Jamal Deen, McMaster University, Canada |
device design and engineering; circuit design and system integration; applications and emerging technologies; materials and fabrication innovations; testing, reliability, and standards | |
We would like to thank everyone who has supported the development of open access publishing. If you would like to create more new journals, you are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com).
2 October 2025
MDPI INSIGHTS: The CEO's Letter #27 - OASPA 2025, COUNTER 5.1, UK Summit in London, MDPI at the Italian Senate
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts


MDPI at OASPA 2025: Embracing the Complexity of Open Access
From 22 to 24 September, I joined the OASPA 2025 Annual Conference in Leuven, Belgium, where the theme, “Embracing the Complexity – How do we get to 100% Open Access?” tackled the hard questions about the future of scholarly communication.
With MDPI a longstanding member of the Open Access Scholarly Publishing Association (OASPA) and Platinum sponsor of the conference, I was invited to present and participate in important discussions on how we can continue to move the needle in Open Access (OA) publishing.
From 50% to 100% Open Access
Last year’s OASPA conference celebrated a major milestone – reaching 50% of global research outputs published as OA. But, as noted during the conference, this was the “easy” part. The challenge ahead is much tougher: how do we take OA from 50% to 100%? For many academics and institutions, OA is still relatively new, and thus it is essential for us to continue educating people as to what OA is, how it works, and why it matters.

Stefan Tochev (CEO, MDPI) presenting at OASPA’s 2025 Annual Conference in Leuven, Belgium.
MDPI’s perspective
At MDPI, we are fully committed to this. As a 100% OA publisher, our growth is inseparable from the success of OA itself. In many ways, MDPI is a byproduct of the global adoption of OA, and we play an important role in helping to advance it further.
I had the opportunity to share MDPI’s perspective in the panel discussion entitled: "Hello from the other side: views from fully Open Access journals using APCs," alongside industry colleagues from PLOS, eLife, AOSIS, and Frontiers.
Instead of giving a standard presentation, I highlighted aspects of MDPI that the audience might not be aware of. I also presented on the opportunities and challenges facing publishers that are already fully OA, the importance of diverse models in achieving 100% OA, and why OA is the baseline while Open Science is the future.
Recognizing Gold OA
As part of the panel, I had undertaken to make some bold and provocative statements. I therefore emphasized a point that is sometimes overlooked: we didn’t reach 50% OA without Gold OA – it accounts for more than half of all OA publications today. And we certainly won’t reach 100% OA without it.
“By educating the community and working together, we can continue to take Open Science to the next level”

“When people speak about Gold OA and MDPI, they should ‘put some respek on our name.”
MDPI is a leader in Gold OA and has been a driver of this progress at scale.
While Gold OA and MDPI are sometimes slighted, both deserve recognition for their contributions to advancing Open Science globally.
I closed my presentation with a reminder that the good we do is sometimes overlooked, and that when people speak about Gold OA and MDPI, they should "put some respek on our name."
I’m pleased to have seen attendees sharing positive experiences with MDPI, reminding us that we bring real value to the OA movement and deserve a stronger reputation. We also engaged in constructive conversations about various topics, including cost transparency.
A few themes that I took away from the conference:
- Quality and integrity matter as much as access. OA publishers must not lose sight of research integrity, inclusivity, and sustainability while pursuing 100% OA.
- Global collaboration is essential. Policies, funding models, and infrastructure differ around the world, and we will need cross-border collaboration to make OA a truly global reality.
- Open Science is the bigger story. OA is just the first step – the future lies in open data, open peer review, research reproducibility, etc.
“MDPI’s scale allows us to better support authors, reinvest in communities, and push Open Science forward”
How we communicate MDPI’s role
For us at MDPI, this is also a reminder of how we communicate externally. When we tell our story, we shouldn’t forget to start with the bigger picture – Open Science and Open Access. Then we connect it to MDPI, our journals, services, and initiatives, exemplifying the fact that we are part of a mission larger than ourselves.

MDPI colleagues Clàudia Aunós (Society Partnerships), Marta Colomer (External Affairs), Stefan Tochev (CEO), and Nikola Paunovic (Scilit), at OASPA’s 2025 Annual Conference in Leuven, Belgium.
The journey to 100% OA will not be simple. But by educating the community and working together, we can continue to take Open Science to the next level.
Impactful Research

MDPI becomes COUNTER 5.1 compliant across 480+ Journals
I’m pleased to share that MDPI has officially become COUNTER 5.1 compliant and has joined the COUNTER Registry.
For those who might not be familiar with it, COUNTER provides international standards for tracking and reporting how research is being used. By becoming COUNTER 5.1 compliant, MDPI can now deliver credible, comparable, and transparent usage reports across our entire journal portfolio.
“MDPI is showing that they want to be measured against the same yardstick as other publishers”
Why is this important?
Because usage statistics aren’t just numbers: they’re powerful tools that help our authors, institutions, and consortia understand the real impact of their research. With COUNTER compliant reports, our institutional partners can now make more informed decisions about publishing agreements, funding allocations, and the long-term value of Open Access.
In practical terms, MDPI will now provide Platform, Title, and Item Reports, with standardized usage views available at the institute and consortium level. These reports cover usage from January 2024 onwards and will be updated monthly. Institutions will be able to access them via SuSy, or automatically through the COUNTER API.

I’d like to highlight and thank Becky Castellon, our Institutional Partnerships Manager, who has played a key role in driving this project forward. Becky captured it perfectly when she said: "Through these usage reports, our global research community can access trustworthy data about how their work is being used and accessed
This information is often vital for reviewing publishing partnership agreements and for making informed decisions about future funding allocations."
We also received encouraging feedback from Tasha Mellins-Cohen, Executive Director at COUNTER Metrics:
"We’re delighted to see born-OA publishers engaging with COUNTER. Our normalised usage metrics are relied on as the basis for credible return-on-investment calculations by libraries worldwide. By adopting the COUNTER standard, MDPI is showing that they want to be measured against the same yardstick as other publishers."
For MDPI, this milestone is another step in our commitment to transparency, trust, and impact. By adopting COUNTER’s standards, we’re not just aligning with best practice; we’re ensuring that Open Access publishing is measured on the same terms as traditional publishing, proving its value in concrete and globally recognized ways.
This is an important milestone for MDPI, but more importantly for the researchers, librarians, and institutions we serve. Transparency builds trust, and COUNTER compliance helps us show the global reach and influence of Open Access publishing in the clearest way possible.
Inside Research

Lin Li (Publisher, MDPI), Stefan Tochev (CEO, MDPI, Prof. Chengkuo Lee (Editor-in-Chief, AI Sensors), and Constanze Schelhorn (Head of Indexing) at restaurant in Basel, Switzerland.
Welcoming Prof. Lee (EiC of AI Sensors) to Basel
On 11 September, we welcomed Prof. Dr. Chengkuo Lee, Editor-in-Chief of our new journal AI Sensors, to our Basel office. Prof. Lee is a high profiled researcher (h-index 104, 37,000+ citations), a longtime collaborator with MDPI (25 published articles), and has already chaired several AI Sensors (AIS)-related conferences with us, including the recent event in Kuala Lumpur, where AI Sensors held its first editorial board meeting.

Stefan Tochev (CEO, MDPI) showing Special Issue reprint books as part of a tour of MDPI’s Basel office.
Every journal has a story
During his visit, we exchanged ideas on how to build the journal’s identity and impact. A key takeaway that I shared was that every journal has a story: its vision, its purpose, and the community it brings together.
That story is what connects with readers and authors, beyond metrics alone.
I encouraged everyone working on journals to reflect: What is the story of your journal? And how can you bring that story to the forefront in how you communicate about it?
How MDPI supports new journals

Constanze Schelhorn (Head of Indexing, MDPI) presenting on the MDPI indexing process at the company’s headquarters in Basel.
We also shared with Prof. Lee how MDPI supports journals through our Institutional Open Access Program, indexing expertise, and the work of our Journal Relationship Specialists.
Launching a new journal is ambitious, but with our strong track record (93% Scopus and 87% Web of Science acceptance rates in 2024), Prof. Lee felt confident that AI Sensors will find its place in the scholarly landscape.
Having spent some hours together, it’s clear that Prof. Lee is not only an Editor-in-Chief but also an ambassador for MDPI. His leadership and collaboration reflect the mission MDPI by which MDPI lives: accelerating Open Access and advancing Open Science.
Special thanks to Constanze Schelhorn (Head of Indexing), Ting Leng (JRS, Managing Editor, AI Sensors), Lin Li (Publisher, AI Sensors), Aimar Xiong (Publisher), and Christian Eberhard (Office Administrator, Basel), for organizing and hosting the meeting.
Coming Together for Science

Highlights from the MDPI UK Summit in London
I was pleased to be back in the UK in September, supporting our Manchester team in hosting their first MDPI Summit in London. This day-and-a-half private event brought together 25 Chief Editors and Associate Editors to exchange knowledge, learn about latest developments at MDPI, and engage in discussions on advancing Open Science. The program included MDPI and guest presentations, and Q&A sessions.
Why these summits matter
Our Summits provide a platform to:
- Share updates on the latest developments at MDPI, our editorial processes, research integrity practices, and indexing.
- Highlight collaborations with institutions and societies in the region.
- Offer external perspectives from guest speakers.
- Create space for Chief Editors to share their insights, ask questions, network, and help shape MDPI’s path forward.
These gatherings are more than updates: they improve our relationships with Chief Editors, who serve not only as leaders of their journals but also as ambassadors for MDPI within the research community. We often hear that this type of event is unique, something many other publishers do not provide. It shows that we care and are willing to go the extra mile to recognize and engage our key collaborators.
|
|
|
|
MDPI and the UK: Key facts
- With over 80,000 publications, the UK is MDPI’s eighth-largest contributor.
- MDPI is the fourth-largest publisher in the UK, accounting for 11% of the country’s 89,526 Open Access publications in 2024.
- We collaborate with more than 4,000 active UK Editorial Board Members, 48% of whom have an H-index above 26. This includes 49 Editors-in-Chief and 74 Section Editors-in-Chief.
- MDPI maintains over 1,000 IOAP agreements worldwide, with 63 from the UK.
“We are willing to go the extra mile to recognize and engage our key collaborators”
|
|
|
|
|
|
|
|
Agenda highlights:
- MDPI Overview, Open Access, and UK Collaboration – Stefan Tochev (CEO, MDPI)
- MDPI Editorial Process – Dr. Michael O’Sullivan (Scientific Quality Advisor Lead, MDPI)
- Research Integrity and Publication Ethics – Daisy Fenton (Research Integrity Specialist, MDPI)
- Institutional Partnerships – Becky Castellon (Institutional Partnerships Manager, MDPI)
- Promoting and Developing Your Journal – Prof. Fabio Tosti (Editor-in-Chief of NDT)
- Indexing to Impact – Dr. Michael O’Sullivan (Scientific Quality Advisor Lead, MDPI)
- Engaging our Academic Community – Jaime Anderson Anderson (UK Operations Manager, MDPI)
- Closing Remarks – Stefan Tochev (CEO, MDPI)

MDPI colleagues Stefan Tochev (CEO), Jaime Anderson Anderson (UK Operations Manager), Dr. Michael O’Sullivan (Scientific Quality Advisor Lead), Becky Castellon (Institutional Partnerships Manager), Daisy Fenton (Research Integrity Specialist) at the MDPI UK 2025 Summit in London.
Thank you!
A special thank-you to the Manchester team and all colleagues behind the scenes who made this Summit a success. Your efforts are greatly appreciated. We look forward to building on this momentum with future Summits in Europe and beyond.
Closing Thoughts

Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI) and Stefan Tochev (CEO, MDPI) participating in a press conference at the Italiane Senate in Rome to promote the 2nd International Conference on Environmental Medicine (ICEM)
MDPI at the Italian Senate: Promoting Environmental Medicine and Open Science
On 16 September, Dr. Giulia Stefenelli (Scientific Communications Lead) and I had the honour of participating in a press conference at the Italian Senate in Rome, organized by the Italian Society of Environmental Medicine (SIMA) to promote the upcoming 2nd International Conference on Environmental Medicine (ICEM) (20–21 November 2025).
This is an important event for MDPI, as we are the exclusive publishing partner for ICEM and have recently launched a new journal with SIMA, further building our presence both in Italy and within this important field of research.
Why this matters
- The promotion of ICEM has received extensive national media coverage (more than 15 mentions in major Italian outlets; see links below).
- The press conference brought together leading policymakers, academics, and Nobel Laureates to emphasize the impact of environmental exposures and epigenetics on human health.
- We were introduced to government ministries, university rectors, and influential stakeholders, which helps us bolster MDPI’s visibility and reputation in Italy.
Highlights
Nobel Laureate Sir Richard Roberts joined the discussion, underlining the importance of environmental medicine in shaping future health outcomes. Nobel Laureate Prof. Dr. Tong Zhu (Peking University) will also speak at the November conference.
Institutional representatives included the Italian Minister of the Environment and Energy Security, the Italian Undersecretary for Health, and senior officials from the World Health Organization.
In my closing remarks, I highlighted that:
“Over the past five years, about 65% of research published in Italy has been Open Access, compared to an average of 55% worldwide.”
Italian research ranked seventh among the top 20 countries in average citations during this period, reflecting its strong international influence. Not only is Italy producing a high volume of research; it is also producing research of outstanding quality.
MDPI’s role
This event was not only about promoting ICEM but also about showcasing MDPI’s commitment to Open Access and our ability to connect scientific publishing with leading academic, medical, and policy institutions.
As Giulia Stefenelli noted:
“This event was highly relevant for MDPI, as it not only showcased our strong commitment to OA but also emphasized our role in advancing important fields such as Environmental Medicine.”
Learn more
- Watch the full press conference (Radio Radicale)
- Giulia’s speech: 33:20 (in Italian)
- Stefan’s speech: 57:50 (in English)
- ICEM 2025 Conference Program
- Selected media coverage:
This moment at the Italian Senate shows how MDPI can connect publishing with science, policy, and society to help advance both Open Science and environmental health research on a global stage.
|
|
|
In Rome with Sir Richard Roberts (photo left) and Prof. Giuseppe Novelli (EiC of MDPI journal COVID).
Chief Executive Officer
MDPI AG
2 October 2025
5th Alpine Winter Conference on Medicinal and Synthetic Chemistry, 25–29 January 2026, St. Anton, Austria
Conference: 5th Alpine Winter Conference on Medicinal and Synthetic Chemistry
Date: 25–29 January 2026
Location: St. Anton, Austria
The Alpine Winter Conference on Medicinal and Synthetic Chemistry presents attending scientists with cutting-edge synthetic and medicinal chemistry, as well as the latest developments in technologies that foster innovation in drug discovery. The main target audience for this highly interdisciplinary meeting includes medicinal and synthetic chemists, as well as participants in related drug discovery disciplines from both industry and academia, including graduate/undergraduate students and postdocs.
For more information about this conference, please visit our website via the following link: https://www.alpinewinterconference.org/.
30 September 2025
Nobel Prize — The Science Behind the Prize
Nobel Prizes are the world’s most prestigious recognition of scientific breakthroughs, honoring discoveries that push the boundaries of knowledge and reshape entire fields. They bring into the public eye researchers whose work might otherwise remain known only within specialized circles.
For many, winning a Nobel Prize is a surreal experience. Laureates often describe a mix of joy, humility, reflection, and gratitude for the teams and collaborators whose contributions made the achievement possible. Behind every Nobel-winning idea lies years of careful, incremental work—a process that often goes unseen.
When Prof. Steven Weinberg won the Nobel Prize in Physics in October 1979, his wife Louise, a legal scholar, reminded him to keep doing the ordinary hard work of science, joking: “Now you have to write some unimportant papers.” True to form, Weinberg continued to push the boundaries of our understanding of the Universe, showing that curiosity and dedication extend far beyond the moment of recognition (Hofmann 2025: https://www.mdpi.com/2073-8994/17/6/840).
Discover the science behind the world’s most transformative ideas
Over the years, dozens of Nobel laureates have published their work with MDPI, entrusting our open access journals to disseminate their findings to a global audience. As of 2024, more than 40 laureates have contributed over 115 articles across 35 journals, ranging from pioneering research on microRNAs and mRNA therapeutics, to fundamental insights in theoretical physics, and advances in structural biology.
We regularly spotlight how Nobel Prize–winning research intersects with the contributions of our authors. This not only celebrates the achievements of the laureates, but also underscores the role of open access in ensuring that transformative science reaches the widest possible audience.
On this page, we invite you to explore selected works by Nobel laureates within the MDPI portfolio, and to join us in celebrating the global impact of their ideas.

The Nobel Prize in Physiology or Medicine 2025 has been awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for for their discoveries concerning peripheral immune tolerance. MDPI sincerely invites you to explore research in a related field.

The Science Behind the Prize: 2025 Nobel Physiology or Medicine Roundtable
6 October 2025, 03:30 pm (CEST)
You are welcome to watch the recording here!
The Nobel Prize in Physics 2025 has been awarded to John Clarke, Michel H. Devoret and John M. Martinis for the discovery of macroscopic quantum mechanical tunnelling and energy quantisation in an electric circuit. MDPI sincerely invites you to explore research in a related field.

The Science Behind the Prize: 2025 Nobel Physics Roundtable
7 October 2025, 02:30 pm (CEST)
You are welcome to watch the recording here!

The Nobel Prize in Chemistry 2025 has been awarded to Susumu Kitagawa, Richard Robson and Omar M. Yaghi for the development of metal-organic frameworks. MDPI sincerely invites you to explore research in a related field.
15 September 2025
Interview with Dr. Po-Han Chao—Winner of the Pharmaceutics Best PhD Thesis Award
We are pleased to share with you a recent interview conducted with Dr. Po-Han Chao, the winner of the Pharmaceutics 2024 Best PhD Thesis Award.
The following is an interview with Dr. Po-Han Chao:
1. Could you introduce your research work during your PhD studies and the main objectives of your doctoral dissertation?
My PhD centered on nanomedicine for cancer immunotherapy. Specifically, I worked on using liposomes to deliver resiquimod, a TLR7/8 agonist, into the tumor microenvironment. My dissertation, entitled “Resiquimod-Loaded Cationic Liposomes Cure Mice with Peritoneal Carcinomatosis and Induce Specific Anti-Tumor Immunity”, showed that this approach not only eradicated tumors in mice via cationic liposomes but also triggered long-lasting, tumor-specific immune memory. The bigger goal was to bring drug delivery and immunotherapy together, finding ways to make the immune system itself fight back against aggressive cancers.
2. Did you encounter any difficulties in carrying out this research? If yes, how did you overcome them and what strategies did you use to stay focused and motivated?
Yes, definitely. Technically, optimizing the liposomes to produce stable formulations with good drug loading took many rounds of trial and error. On top of that, the COVID-19 lockdowns made things harder because lab access was restricted for long stretches of time. That slowed down experiments and added a lot of uncertainty about timelines. What helped me was breaking the work into smaller milestones and focusing on what I could do outside the lab, like analyzing data or planning the next set of experiments. Talking with my supervisor and lab mates kept me grounded, and celebrating small wins along the way helped me stay motivated. Ultimately, I reminded myself of the bigger picture—that this research could contribute to new treatment options for patients who really need them.
3. In your opinion, what key qualities should an excellent PhD graduate possess? Do you have some advice for doctoral students who have not yet graduated?
I would say resilience, curiosity, and clear communication. Resilience because experiments will fail more often than they succeed, curiosity because that is what keeps you digging deeper, and communication because good science needs to be shared in a way that others can understand and use. For students still on their journey, do not measure your progress only by papers or data points. The PhD is about developing how you think, troubleshoot, and collaborate. Those skills stay with you much longer than a single publication.
4. What are your future research plans and what are your long-term career goals?
I want to keep working at the intersection of nanomedicine and cancer immunotherapy, with a focus on translating preclinical findings into clinically viable treatments. Long term, my goal is to bridge academia and industry to help move innovative therapies from the lab into clinical trials, where they can make a real difference for patients with advanced cancers.
5. As an author, what factors do you consider most important when choosing a journal for publication? Pharmaceutics is an open access journal—what are your thoughts on the open access publishing model?
When I choose a journal, I look for the right audience, a fair and constructive review process, and good visibility. The whole point is to make sure the research reaches the people who can use it and build on it. For open access, I think it is really valuable. It removes barriers and makes science accessible not only to researchers but also clinicians and even patients. Fees can be challenging, but overall, I see open access as the right direction for science as it makes knowledge more inclusive and accelerates collaboration.
12 September 2025
Meet Us at the 2025 Chinese Biomaterials Congress (CSBM 2025), 9–12 October 2025, Shaoxing, China
Conference: 2025 Chinese Biomaterials Congress (CSBM 2025)
Date: 9–12 October 2025
Location: Shaoxing, China
MDPI will be attending the 2025 Chinese Biomaterials Congress as an exhibitor. We welcome researchers from different backgrounds to visit and share their latest ideas with us.
The Chinese Biomaterials Congress is the most comprehensive, largest, and highest-level comprehensive academic exchange platform in its field. The 2025 Chinese Biomaterials Congress ence and Exhibition of New Technologies, Products, and Instruments (CSBM 2025), hosted by the Chinese Society for Biomaterials and organized by the Zhejiang University Shaoxing Research Institute, will be held at the Zhejiang Shaoxing International Convention and Exhibition Center from 9 to 12 October 2025. Driven by the new quality productivity policy, biomaterials, as a key area of strategic emerging industries, are experiencing unprecedented development opportunities.
The conference will focus on cutting-edge biomaterials science, technological innovation, application of research findings, and regulatory science, sharing the latest research findings and practical experiences and discussing the future direction of the biomaterials field. Experts, scholars, researchers, physicians, and entrepreneurs from renowned research institutions, medical institutions, businesses, and regulatory agencies, engaged in the research, development, production, testing, regulation, and clinical practice of biomaterials and medical devices, will attend.
Here is a list of just a few of the cutting-edge topics for all:
1. Innovative bone regeneration biomaterials and bone health;
2. Cardiovascular and peripheral vascular materials and devices;
3. Advanced manufacturing cutting-edge technologies;
4. Tissue and organ regenerative medicine materials;
5. Biomedical metal materials;
6. Nanobiomaterials and pharmaceutical development;
The following MDPI journals will be represented:
If you are planning to attend this conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://2025.csbm.org.cn/.

















































